Linked Life Data

18055102

Source:http://linkedlifedata.com/resource/pubmed/id/18055102

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2008-3-4
pubmed:abstractText
Defective glutamate (glu) metabolism and excitotoxicity have been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS). Moreover, glycine (gly) has been shown to potentiate excitatory transmission. The "antiglutamatergic" agent riluzole has been shown to prolong survival in ALS. The aim of the study was to investigate a possible effect of riluzole on plasma glu and gly levels, correlating with clinical response to treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0303-8467
pubmed:author
pubmed:issnType
Print
pubmed:volume
110
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
222-6
pubmed:dateRevised
2009-10-14
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: the effect of riluzole treatment.
pubmed:affiliation
Department of Neurology, Athens National University, Aeginition Hospital, 74, Vas. Sophia's Ave., 11528 Athens, Greece. eandread@med.uoa.gr
pubmed:publicationType
Journal Article